Overview:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy that presents significant diagnostic and treatment challenges. While tagraxofusp remains the only approved therapy, an expanding CD123-directed pipeline—including pivekimab sunirine, bispecific antibodies, and CAR T-cell therapies—is reshaping the treatment landscape and creating a need for clinicians to stay current with emerging evidence.
This Medical Crossfire® program will feature expert-led,
case-based discussions on diagnosis, frontline treatment strategies, emerging
CD123-directed therapies, and multidisciplinary care. The debate-driven format
will help clinicians interpret new data and apply evolving evidence to the
management of patients with BPDCN.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Differentiate BPDCN from clinically and pathologically overlapping entities using integrated immunophenotypic, cytogenetic, and molecular criteria
- Compare efficacy and toxicity profiles of FDA-approved and investigational therapies when prioritizing frontline and relapsed/refractory treatment options
- Implement evidence-based protocols for capillary leak syndrome prevention and management while preserving treatment intensity in patients with BPDCN
- Integrate transplant referral, clinical trial enrollment, and multidisciplinary supportive care into BPDCN treatment plans tailored for older adults, pediatric and AYA patients, and patients with CNS involvement
Target Audience:
This educational activity is directed toward
hematologist-oncologists, advanced practice providers, nurses, NPs/PAs,
pharmacists, dermatopathologists, hematopathologists, and other HCPs involved
in the diagnosis and treatment of BPDCN.
Andrew A. Lane, MD, PhD
Chief, Division of Hematologic Neoplasia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA
Marlise Luskin, MD, MSCE
Associate Program Director, Fellowship Program
Educational Director, Adult Leukemia Program Senior
Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Kendra Sweet, MD
Associate Member, Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Assistant Professor, Department of Oncologic Sciences
University of South Florida Morsani College of Medicine
Tampa, FL
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’
Education Resource®, LLC is approved by the California Board of
Registered Nursing, Provider #16669, for 1.5 Contact Hours.